-
公开(公告)号：US07709480B2
公开(公告)日：2010-05-04
申请号：US11313380
申请日：2005-12-21
申请人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
发明人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
IPC分类号： C07D417/00 , C07D239/48 , A61K31/506
CPC分类号： C07D239/48 , C07D231/12 , C07D233/56 , C07D239/50 , C07D239/80 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D451/04 , C07D451/06 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10
摘要： The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
摘要翻译： 本发明涉及式（I）的三取代嘧啶，其中0Ra至Re如权利要求1所定义，其适用于治疗以细胞增殖过度或异常为特征的疾病，其用于制备具有上述药物组合物的用途 性质及其制备方法。
-
公开(公告)号：US07173028B2
公开(公告)日：2007-02-06
申请号：US10271763
申请日：2002-10-16
申请人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
发明人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
IPC分类号： C07D417/10 , C07D239/48 , A61K31/506
CPC分类号： C07D239/48 , C07D231/12 , C07D233/56 , C07D239/50 , C07D239/80 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D451/04 , C07D451/06 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10
摘要： The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
摘要翻译： 本发明涉及如权利要求1所定义的式（I）的三取代嘧啶，其中R 1和R 2定义如权利要求1所述，其适用于治疗以过量为特征的疾病 或异常细胞增殖，其用于制备具有上述性质的药物组合物的用途及其制备方法。
-
公开(公告)号：US08420630B2
公开(公告)日：2013-04-16
申请号：US12711364
申请日：2010-02-24
申请人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
发明人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
IPC分类号： C07D239/48 , C07D403/12 , C07D401/12 , A61K31/506
CPC分类号： C07D239/48 , C07D231/12 , C07D233/56 , C07D239/50 , C07D239/80 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D451/04 , C07D451/06 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10
摘要： The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
摘要翻译： 本发明涉及式（I）的三取代嘧啶，其中0Ra至Re如权利要求1所定义，其适用于治疗以细胞增殖过度或异常为特征的疾病，其用于制备具有上述药物组合物的用途 性质及其制备方法。
-
公开(公告)号：US20060100211A1
公开(公告)日：2006-05-11
申请号：US11313380
申请日：2005-12-21
申请人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
发明人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
IPC分类号： C07D403/02 , A61K31/501 , A61K31/506
CPC分类号： C07D239/48 , C07D231/12 , C07D233/56 , C07D239/50 , C07D239/80 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D451/04 , C07D451/06 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10
摘要： The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
摘要翻译： 本发明涉及如权利要求1所定义的式（I）的三取代嘧啶，其中R 1和R 2定义如权利要求1所述，其适用于治疗以过量为特征的疾病 或异常细胞增殖，其用于制备具有上述性质的药物组合物的用途及其制备方法。
-
公开(公告)号：US07691888B2
公开(公告)日：2010-04-06
申请号：US11243796
申请日：2005-10-05
申请人： Bodo Betzemeier , Trixi Brandl , Steffen Breitfelder , Ralph Brueckner , Thomas Gerstberger , Michael Gmachl , Matthias Grauert , Frank Hilberg , Christoph Hoenke , Matthias Hoffmann , Maria Impagnatiello , Dirk Kessler , Christian Klein , Bernd Krist , Udo Maier , Darryl McConnell , Charlotte Reither , Stefan Scheuerer , Andreas Schoop , Norbert Schweifer , Oliver Simon , Martin Steegmaier , Steffen Steurer , Irene Waizenegger , Ulrike Weyer-Czernilofsky , Andreas Zoephel
发明人： Bodo Betzemeier , Trixi Brandl , Steffen Breitfelder , Ralph Brueckner , Thomas Gerstberger , Michael Gmachl , Matthias Grauert , Frank Hilberg , Christoph Hoenke , Matthias Hoffmann , Maria Impagnatiello , Dirk Kessler , Christian Klein , Bernd Krist , Udo Maier , Darryl McConnell , Charlotte Reither , Stefan Scheuerer , Andreas Schoop , Norbert Schweifer , Oliver Simon , Martin Steegmaier , Steffen Steurer , Irene Waizenegger , Ulrike Weyer-Czernilofsky , Andreas Zoephel
IPC分类号： A61K31/429 , A61K31/4162 , C07D513/02 , C07D417/14
CPC分类号： C07D513/04 , C07D277/84
摘要： The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
摘要翻译： 本发明包括通式（1）的化合物，其中R 1至R 3如权利要求1中所定义，其适用于治疗特征为过度或异常细胞增殖的疾病，以及其用于制备具有上述 属性。
-
公开(公告)号：US08207349B2
公开(公告)日：2012-06-26
申请号：US12685213
申请日：2010-01-11
申请人： Bodo Betzemeier , Trixi Brandl , Steffen Breitfelder , Ralph Brueckner , Thomas Gerstberger , Michael Gmachl , Matthias Grauert , Frank Hilberg , Christoph Hoenke , Matthias Hoffmann , Maria Impagnatiello , Dirk Kessler , Christian Klein , Bernd Krist , Udo Maier , Darryl McConnell , Charlotte Reither , Stefan Scheuerer , Andreas Schoop , Norbert Schweifer , Oliver Simon , Martin Steegmaier , Steffen Steurer , Irene Waizenegger , Ulrike Weyer-Czernilofsky , Andreas Zoephel
发明人： Bodo Betzemeier , Trixi Brandl , Steffen Breitfelder , Ralph Brueckner , Thomas Gerstberger , Michael Gmachl , Matthias Grauert , Frank Hilberg , Christoph Hoenke , Matthias Hoffmann , Maria Impagnatiello , Dirk Kessler , Christian Klein , Bernd Krist , Udo Maier , Darryl McConnell , Charlotte Reither , Stefan Scheuerer , Andreas Schoop , Norbert Schweifer , Oliver Simon , Martin Steegmaier , Steffen Steurer , Irene Waizenegger , Ulrike Weyer-Czernilofsky , Andreas Zoephel
IPC分类号： C07D277/60
CPC分类号： C07D513/04 , C07D277/84
摘要： The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
摘要翻译： 本发明包括通式（1）的化合物，其中R 1至R 3如权利要求1中所定义，其适用于治疗特征为过度或异常细胞增殖的疾病，以及其用于制备具有上述 属性。
-
公开(公告)号：US20060100254A1
公开(公告)日：2006-05-11
申请号：US11243796
申请日：2005-10-05
申请人： Bodo Betzemeier , Trixi Brandl , Steffen Breitfelder , Ralph Brueckner , Thomas Gerstberger , Michael Gmachl , Matthias Grauert , Frank Hilberg , Christoph Hoenke , Matthias Hoffmann , Maria Impagnatiello , Dirk Kessler , Christian Klein , Bernd Krist , Udo Maier , Darryl McConnell , Charlotte Reither , Stefan Scheuerer , Andreas Schoop , Norbert Schweifer , Oliver Simon , Martin Steegmaier , Steffen Steurer , Irene Waizenegger , Ulrike Weyer-Czernilofsky , Andreas Zoephel
发明人： Bodo Betzemeier , Trixi Brandl , Steffen Breitfelder , Ralph Brueckner , Thomas Gerstberger , Michael Gmachl , Matthias Grauert , Frank Hilberg , Christoph Hoenke , Matthias Hoffmann , Maria Impagnatiello , Dirk Kessler , Christian Klein , Bernd Krist , Udo Maier , Darryl McConnell , Charlotte Reither , Stefan Scheuerer , Andreas Schoop , Norbert Schweifer , Oliver Simon , Martin Steegmaier , Steffen Steurer , Irene Waizenegger , Ulrike Weyer-Czernilofsky , Andreas Zoephel
IPC分类号： A61K31/429 , C07D513/02
CPC分类号： C07D513/04 , C07D277/84
摘要： The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in Claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
摘要翻译： 本发明包括通式（1）的化合物，其中R 1至R 3定义如权利要求1，其适用于治疗以下特征的疾病： 过度或异常细胞增殖，以及它们用于制备具有上述性质的药物。
-
公开(公告)号：US20070004684A1
公开(公告)日：2007-01-04
申请号：US11423008
申请日：2006-06-08
申请人： Peter Sennhenn , Andreas Mantoulidis , Matthias Treu , Ulrike Tontsch-Grunt , Walter Spevak , Darryl McConnell , Andreas Schoop , Ralph Brueckner , Albrecht Jacobi , Ulrich Guertler , Gisela Schnapp , Christian Klein , Frank Himmelsbach , Alexander Pautsch , Bodo Betzmeier , Lars Herfurth , Juergen Mack , Dieter Wiedenmayer , Gerd Bader , Ulrich Reiser
发明人： Peter Sennhenn , Andreas Mantoulidis , Matthias Treu , Ulrike Tontsch-Grunt , Walter Spevak , Darryl McConnell , Andreas Schoop , Ralph Brueckner , Albrecht Jacobi , Ulrich Guertler , Gisela Schnapp , Christian Klein , Frank Himmelsbach , Alexander Pautsch , Bodo Betzmeier , Lars Herfurth , Juergen Mack , Dieter Wiedenmayer , Gerd Bader , Ulrich Reiser
IPC分类号： A61K31/4745 , C07D471/02 , A61K31/655
CPC分类号： C07D471/04
摘要： The present invention encompasses compounds of general formula (1) wherein R2 to R5 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
摘要翻译： 本发明包括通式（1）的化合物，其中R 2至R 5和X如权利要求1中所定义，其适用于治疗以下特征的疾病： 过度或异常细胞增殖，以及其用于制备具有上述性质的药物组合物的用途。
-
公开(公告)号：US20060148800A1
公开(公告)日：2006-07-06
申请号：US11206703
申请日：2005-08-17
申请人： Heinz Stadtmueller , Harald Engelhardt , Martin Steegmaier , Anke Baum , Ulrich Guertler , Andreas Schoop , Jen Quant , Flavio Solca , Rudolf Hauptmann , Ulrich Reiser , Stephan Zahn , Lars Herfurth
发明人： Heinz Stadtmueller , Harald Engelhardt , Martin Steegmaier , Anke Baum , Ulrich Guertler , Andreas Schoop , Jen Quant , Flavio Solca , Rudolf Hauptmann , Ulrich Reiser , Stephan Zahn , Lars Herfurth
IPC分类号： A61K31/53
CPC分类号： C07D239/42 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/08 , C07D491/10
摘要： The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
-
公开(公告)号：US20060047118A1
公开(公告)日：2006-03-02
申请号：US11211048
申请日：2005-08-24
IPC分类号： C07D487/02 , C07D475/02
CPC分类号： C07D471/04 , C07D487/04
摘要： Disclosed compounds of general formula (1) wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3 and R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.
摘要翻译： 公开的通式（1）的化合物，其中L，Q 1，Q 2，X，Y，R a，R b， R 1，R 2，R 2，R 3，R 4和R 4， 如权利要求1中所定义的，其适用于治疗以细胞增殖过度或异常为特征的疾病，以及其用于制备具有上述性质的药物组合物的用途。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.08 秒)
